Ai-powered platform for predicting allergen and sensitivity risks in food
Absentia Labs offers an AI platform that predicts allergenicity and sensitivity risks of food ingredients by simulating human biological responses in silico. This tool enhances R&D by enabling high-throughput, human-relevant screening without animal tests.
Overview
Absentia Labs has developed an innovative AI-powered platform that enables the prediction of allergenicity and sensitivity risks in novel food ingredients. By simulating human biological responses in silico, this technology aids in the early detection of potential adverse reactions across various organ systems. Designed to integrate comprehensive biomedical data, including omics and tissue-specific gene expression, the platform provides a human-relevant, non-animal testing approach to enhance consumer safety and accelerate product development.
Technical specifications
Key features:
- AI-driven immune pathway simulation: Models immune and inflammatory responses to detect allergenic potential.
- Data integration: Combines omics data with receptor-ligand interactions and gene expression profiles.
- High-throughput capability: Supports rapid screening of multiple compounds to accelerate R&D processes.
- Interpretable results: Provides clear, actionable insights for formulation decisions.
- Regulatory alignment: Facilitates compliance with industry standards for safety assessments.
Technology readiness level
This technology is currently at Technology Readiness Level 5, indicating that it has been validated in relevant environments through pilot studies. The platform has successfully identified known allergens and is poised for further collaborative validation to refine its predictive accuracy and application scope.
About Absentia Labs
Absentia Labs is an AI-biology company that develops foundation models designed to predict the behavior of medicines within the human body. By leveraging biological, chemical, and clinical data, the company's in-silico platform aims to transform drug discovery from an experimental science into a predictive, computable process. Their technology models drug efficacy and safety, helping to identify organ-specific risks early and providing a scalable alternative to traditional, slower, and often less reliable methods of preclinical testing. The company's work has been recognized by organizations such as the FDA, which accepted their AI-driven digital liver model into its ISTAND qualification program.
This technology is intended to help pharmaceutical companies and researchers streamline drug development, reduce costs, and minimize reliance on animal testing. By enabling more accurate, data-driven decisions in the early stages of therapeutic research, Absentia Labs aims to accelerate the delivery of safer medicines to patients and improve overall success rates in drug development. Founded as a spin-out from MIT research, the Boston-based startup is focused on addressing fundamental bottlenecks in the pharmaceutical industry by applying frontier AI research to practical, real-world biological challenges.
Inquire about this partnering listing
Industry applications
delivered to your inbox.